Replies to post #3092 on Keryx Biopharmaceuticals Inc fka KERX

[H2R]

Maybe this is what's confusing the market:

Given the potential of the additional Auryxia indication on future prescription demand and the dynamics surrounding Auryxia’s payer mix, prescription demand growth and the resulting net U.S. Auryxia product sales in the third quarter, Keryx is withdrawing its 2017 financial guidance.

Which may sound ominous to some.

Long KERX